The period in brief – financial summary for the second quarter
- Net sales amounted to
SEK 0 million (SEK 0 ). - R&D expenses amounted to
SEK 16.5 million (SEK 14.7 million ). - Operating income for the second quarter amounted to
SEK -18.3 million (SEK -15.4 million ). Income after financial items for the second quarter amounted toSEK -18.2 million (SEK -15.6 million ). - Earnings per share, before and after dilution, for the second quarter amounted to
SEK -0.22 (SEK-0.28 ). - Cash flow from operating activities for the second quarter amounted to
SEK -14.8 million (SEK -14.4 million ). - As of
June 30 , equity amounted toSEK 76.9 million (SEK 95.0 million ) orSEK 0.94 (SEK 1.69 ) per share. - The equity/assets ratio on
June 30 2023 was 84 percent (87 percent). - Cash and cash equivalents on
June 30 2023 amounted toSEK 67.0 million (SEK 82.3 million ).
Significant events during the second quarter
Kancera reported that the company has submitted the regulatory application to conduct a First-In- Human study of its fractalkine blocker KAND145.Kancera reported that patient screening to the KANDOVA-study, a combined phase Ib/IIa study of the fractalkine blocker KAND567 in ovarian cancer patients, has been started.Kancera reported the outcome of the exercise period for warrants of series TO6: approx.. 25 percent of outstanding warrants were utilized adding approximatelySEK 5.9 million (before transaction costs) in cash toKancera .Kancera reported thatPeter Selin is appointed as new Chief Executive Officer as ofJuly 1 2023 .Kancera reported that the first patient in the KANDOVA study has been dosed with KAND567.
Important events after the end of the period
- USPTO has granted a product patent for KAND567, manufactured according to Kancera’s patented manufacturing process, that enables
Kancera to apply for data exclusivity and market protection for up to 7.5 year for the first indication approved inthe United States .
About
For further information:
CEO,
Phone: +46 (0)8-5012 60 80
Visit Kancera’s web page: https://www.kancera.com/en
This information is information that
© Modular Finance, source